A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Gastroenterology Année : 2011

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C

Résumé

BACKGROUND & AIMS: Therapy for chronic hepatitis C (CHC) has limited efficacy, adverse effects, and high costs. Cohort and vaccine-based preclinical studies have indicated the importance of T-cell-based immunity in controlling viral infection. TG4040 is a recombinant poxvirus vaccine that expresses the hepatitis C virus (HCV) proteins NS3, NS4, and NS5B. We performed a phase I clinical trial to assess the safety, immunogenicity, and early antiviral efficacy of TG4040 in patients with CHC. METHODS: In an open-label, dose-escalating study, patients with mild CHC (genotype 1) were assigned to 3 groups of 3 patients each; they received subcutaneous injections of 10⁶, 10⁷, or 10⁸ plaque-forming units of TG4040 on study days 1, 8, and 15. Six additional patients were given the highest dose of vaccine (10⁸ plaque-forming units). Patients were followed for 6 months after the last injection. T-cell-based and antibody responses and levels of HCV RNA were measured. RESULTS: All 3 doses of TG4040 were well tolerated, without serious adverse events. Vaccine-induced HCV-specific cellular immune responses were observed in 5 of the 15 patients (33%). A transient decrease in circulating levels of HCV RNA, from -0.52 log₁₀ to -1.24 log₁₀, was observed in 8 patients; in 5 patients, the lowest level of HCV RNA was observed on day 37, after the first injection. The most pronounced decrease in viral load occurred in 2 patients, who also had marked vaccine-induced T-cell responses. CONCLUSIONS: In patients with CHC, the viral-vector-based vaccine TG4040 had a good safety profile, induced HCV-specific cellular immune responses, and reduced viral load. This vaccine should be investigated in further clinical studies, in combination with standard of care.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-00827965 , version 1 (30-05-2013)

Identifiants

Citer

François Habersetzer, Géraldine Honnet, Christine Bain, Marianne Maynard-Muet, Vincent Leroy, et al.. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology, 2011, 141 (3), pp.890-899.e1-4. ⟨10.1053/j.gastro.2011.06.009⟩. ⟨hal-00827965⟩
271 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More